Compounds Studied in Cognitive and Neuroprotection Research

Research context

This page surveys compounds held in our catalogue that appear in the cognitive and neuroprotection research literature. It is written for laboratory and preclinical researchers and does not address human use.

The work in this area centres on mitochondrial function, neurotrophic signalling, and the resolution of neuroinflammatory tone — the pathways most frequently interrogated when cognitive endpoints are measured in animal models.

Research Studies

BPC-157 and tendon healing after rotator cuff repair

BPC-157 is a synthetic pentadecapeptide. A randomized, double-blind, placebo-controlled pilot trial is investigating its effects on tendon healing and functional recovery following arthroscopic rotator cuff repair; twenty patients self-administer subcutaneous injections daily for 90 days after surgery. The protocol notes that BPC-157 has shown regenerative and anti-inflammatory effects in preclinical animal models of musculoskeletal injury but has not previously been studied in formal human clinical trials [7].

BPC-157 and TB-500 in musculoskeletal repair models

The BPC-157 and TB-500 combination is supplied as a blended research material. The evidence block for this page does not contain a study specific to the blend; the individual components are represented in the musculoskeletal literature cited above [7].

Cerebrolysin and neurotrophic support in cognitive models

Cerebrolysin is a peptide preparation used in neuroprotection research. The evidence block for this page does not contain a study specific to Cerebrolysin, and no claim is made here about its effects.

Epithalon and telomere-related endpoints

Epithalon (Epitalon) is a synthetic tetrapeptide studied in the context of telomerase and cellular ageing research. The evidence block for this page does not contain a study specific to Epithalon, and no claim is made here about its effects.

Nicotinamide and retinal protection in primary open-angle glaucoma

The NADIR trial is testing whether high-dose nicotinamide, a vitamin B3 supplement, protects retinal nerve cells in adults with primary open-angle glaucoma already receiving standard eye drops or laser treatment. The primary question is whether adding nicotinamide slows the rate of thinning of the inner retinal nerve cell layer, measured by a non-invasive eye scan, compared with standard therapy alone over 12 months. Participants are randomized to nicotinamide tablets starting at 1.5 grams per day or to standard therapy [3].

Nicotinamide riboside and walking distance in peripheral artery disease

The NICE-PAD II trial randomizes 250 participants with peripheral artery disease aged 50 and older to nicotinamide riboside or placebo for six months. The primary outcome is change in six-minute walk distance at six-month follow-up; secondary outcomes include the Walking Impairment Questionnaire distance score, PROMIS Mobility score, and calf muscle perfusion measured by magnetic resonance arterial spin labelling [11].

Semaglutide and cardiometabolic risk in schizophrenia with metabolic syndrome

A multicentre, double-blind, placebo-controlled randomized trial is evaluating whether adjunctive oral semaglutide 3 mg once daily, added to treatment as usual, reduces 10-year cardiovascular risk (QRISK3) and improves insulin resistance, lipids, weight and metabolic biomarkers over 24 weeks in patients with schizophrenia on second-generation antipsychotics, while confirming psychiatric safety and tolerability [9].

Semaglutide and postpartum cardiometabolic risk after gestational diabetes

An effectiveness-implementation Hybrid Type 1 randomized trial is evaluating immediate postpartum semaglutide following a pregnancy complicated by gestational diabetes mellitus. A total of 226 postpartum individuals are randomized 1:1 to semaglutide or standard postpartum care for a 6-month active treatment phase, with the primary effectiveness outcome being development of metabolic syndrome at 6 months postpartum [2].

Tirzepatide and preoperative optimization before gastric bypass

A study compares three preoperative strategies before one anastomosis gastric bypass for severe obesity: tirzepatide for 60 days, a ketogenic diet for 4 weeks, or standard care. The main goal is to determine which approach leads to the best weight loss one year after surgery, with secondary evaluation of safety, surgical outcomes, and improvement of obesity-related conditions including diabetes, high blood pressure, and sleep apnea [5].

GLP-1/GIP receptor agonists in obesity-related HFpEF

GLIDE-HF is a prospective, single-centre, non-interventional observational cohort registry conducted within routine outpatient heart failure care in Poland. It enrols patients with obesity-related heart failure with preserved ejection fraction, defined by chronic heart failure symptoms or exertional dyspnoea, body mass index at least 30 kg/m2, left ventricular ejection fraction at least 50%, and objective evidence of HFpEF using contemporary diagnostic scores, without a dominant alternative cause of dyspnoea [8].

HMB plus vitamin D3 and muscle preservation during semaglutide initiation

A randomized, double-blind, placebo-controlled trial is evaluating whether daily calcium beta-hydroxy-beta-methylbutyrate plus vitamin D3 preserves muscle mass, physical function, and resting metabolism in adults aged 65 to 85 years with type 2 diabetes newly starting semaglutide as part of usual clinical care. The primary outcome is change in appendicular lean mass measured by dual-energy X-ray absorptiometry from baseline to month 6 [10].

SYH2069 and glycaemic control in type 2 diabetes

A multicentre, randomized, double-blind, placebo and active-controlled, dose-finding phase 2 study is evaluating the efficacy, safety, pharmacokinetics and immunogenicity of SYH2069 injection in participants with type 2 diabetes mellitus with inadequate glycaemic control on diet and exercise alone or metformin monotherapy. A total of 240 subjects are enrolled across a 2-week screening period, 3-week run-in, 28-week treatment period and 3-week safety follow-up [12].

Fasting regimens and mitophagy markers

A study is investigating how different types of fasting affect mitochondrial clearance and renewal. It compares Ramadan dry fasting, which restricts both food and fluids from dawn to sunset, with standard 16:8 time-restricted feeding, which permits water. The study examines whether the combined effects of fluid restriction and daily body rhythms trigger a stronger mitophagy response, and measures blood markers related to mitochondrial DNA and metabolic health across a 30-day period [4].

GHK and GHK-Cu blood levels after patch application

A two-part clinical trial is investigating GHK and GHK-Cu blood levels before and after intervention in healthy adults, and the efficacy of the X39 patch on those levels compared with placebo. The main questions are the change in GHK and GHK-Cu levels from baseline to Day 8, and the difference in that change between the X39 patch and placebo [6].

AI-assisted subtyping in acute aortic dissection

A prospective multicentre randomized controlled trial is integrating multi-dimensional data to construct an AI immunoinflammatory subtyping system for acute aortic dissection, enabling rapid subtyping and establishing a subtyping-target-treatment closed loop for emergency needs. Three hundred patients are randomized to subtyping-based precision therapy or empirical strategies [1].

Comparison of selected trials

If you are reading this for personal health reasons

All materials described on this page are sold strictly for laboratory research use. We do not provide dosing information, medical guidance, or recommendations for human use. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection — https://clinicaltrials.gov/study/NCT07382375
• [2] Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes — https://clinicaltrials.gov/study/NCT07797036
• [3] Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial) — https://clinicaltrials.gov/study/NCT07808333
• [4] Mitophagy and Mitochondrial DNA Dynamics During Ramadan Dry Fasting vs 16:8 Time-Restricted Feeding — https://clinicaltrials.gov/study/NCT07638696
• [5] Preoperative Optimization With Tirzepatide, Ketogenic Diet, or Standard Care Before One Anastomosis Gastric Bypass Surgery — https://clinicaltrials.gov/study/NCT07622992
• [6] Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults — https://clinicaltrials.gov/study/NCT07706361
• [7] Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery — https://clinicaltrials.gov/study/NCT07803250
• [8] GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry — https://clinicaltrials.gov/study/NCT07787936
• [9] Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome — https://clinicaltrials.gov/study/NCT07770282
• [10] HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide — https://clinicaltrials.gov/study/NCT07760948
• [11] The NICE-PAD II Trial — https://clinicaltrials.gov/study/NCT07782671
• [12] A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin — https://clinicaltrials.gov/study/NCT07796477